Abstract 399P
Background
Due to the lack of studies on unfit patients with gastric cancer (GC) who did not receive any aggressive cancer treatment—best supportive care (BSC) cases—their long-term prognosis remains unclear, especially for those harboring potentially curable disease (clinical stage [cStage] I–III). Therefore, clinicians sometimes have trouble answering unfit patients or their caregivers when asked questions such as “How long will I live without any anticancer treatment?”. Hence, we conducted this observational study to capture the real-world data of baseline characteristics, provided supportive care, and long-term outcomes for BSC cases.
Methods
Consecutive clinical records of patients with GC diagnosed at Steel Memorial Muroran Hospital (SMMH) from January 2017 to December 2021 were collected and analyzed. We conducted this study with the approval of the Institutional Review Board of SMMH (#J230103). The primary outcome of this study is overall survival (OS).
Results
Of 481 patients diagnosed with GC, 91 (18.9%) were BSC cases; their median age was 85 (range: 46–96) years, and 75.8% were male. BSC cases showed a very high risk of receiving aggressive cancer treatment with a median Age-Adjusted Charlson Comorbidity Index score of 7 and a G-8 score of 7. The median OS for all patients was 3.9 months (95% confidence interval [CI]: 3.0–5.4). The median OS was 12.4, 8.3, and 2.5 months for cStage I, II–III, and IV, respectively. Patients with potentially curable GC (cStage I–III) had significantly longer OS than those with incurable disease (cStage IV), with a hazard ratio for death of 0.29 (95% CI: 0.18–0.47, p<0.0001). The percentage of death by GC in a total number of deaths also increased with increasing stage. Pneumonia and heart failure were the most common cause of death among cases who died other than GC. After diagnosis, cStage I patients were more likely to prefer to stay where they had lived (nursing homes or their own house), while more advanced stage patients chose hospice.
Conclusions
The median OS of BSC cases in poor general condition was ∼1 year for cStage I, 8 months for cStage II–III, and < 3 months for cStage IV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Takada: Financial Interests, Personal, Invited Speaker: Eisai, Janssen, Chugai, Ono, Otsuka, Daiichi Sankyo, Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract